NCT03044132View on ClinicalTrials.gov

DermACELL AWM® in Chronic Wagner Grade 3/4 Diabetic Foot Ulcers

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 15, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

December 31, 2018

Conditions
Diabetic Foot UlcerLower Extremity Wound
Interventions
OTHER

DermACELL AWM

Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology

Trial Locations (2)

27804

Purvis Moyer Foot and Ankle Center, Rocky Mount

93710

Limb Preservation Platform, Fresno

Sponsors

Lead Sponsor

LifeNet Health
All Listed Sponsors
lead

LifeNet Health

INDUSTRY

NCT03044132 - DermACELL AWM® in Chronic Wagner Grade 3/4 Diabetic Foot Ulcers | Biotech Hunter | Biotech Hunter